As blocking TNF-α can lead to increased IL-17 production, which is counterproductive in several IL-17-driven autoimmune diseases (such as HS and VHK or VKHLD as described here), disease exacerbations or new autoimmune diseases during TNF-α blocker therapy should be carefully monitored. This evidence concerns the gene IL17A and autoimmune disease.